VSIR and ovarian carcinoma: However, this study is the first to confirm that Tfr cells are key mediators of VISTA’s inhibitory effect on CD8+ T cells, and that this inhibition can be reversed by silencing VISTA, suggesting that targeting VISTA may restore CD8+ T cell anti-tumor activity—with potential implications for ovarian cancer.